Regeneron Ophthalmology Deal History & Licensing Activity
Regeneron Ophthalmology is a large biotech headquartered in US. Over the past three years, Regeneron Ophthalmology has been involved in 4 licensing and acquisition transactions, with a primary focus on ADC (4 deals).
Deals (12mo)
3
Active Trials
25
Top Modality
ADC
Focus Area
Mega Deals
Regeneron Ophthalmology Recent Deal Activity
Licensing, acquisition, and partnership transactions involving Regeneron Ophthalmology in the past 12 months.
| Asset | Partner | Modality | Phase | Type | Date |
|---|---|---|---|---|---|
| ADC platform collaboration | Regeneron | ADC | Discovery | collaboration | May 2026 |
| Parabilis ADC platform | Regeneron | ADC | Discovery | collaboration | May 2026 |
| radiopharma program | Regeneron | Radiopharmaceuticals | Unknown | license | Apr 2026 |
Regeneron Ophthalmology Pipeline Focus
Therapeutic areas and modalities where Regeneron Ophthalmology is most active based on deal history and clinical trial data.
Therapeutic Areas
Modalities
Regeneron Ophthalmology Strategic Signals
Key indicators of Regeneron Ophthalmology's licensing and acquisition strategy, including patent expirations, pipeline gaps, and strategic priorities.
Patent Cliffs
- Undisclosed—
Strategic Profile
Acquisition Appetite
Strategic Priorities
See How Your Asset Matches Regeneron Ophthalmology's Portfolio
Use our deal calculator to benchmark upfront payments, milestones, and royalties for Mega Deals assets — powered by data from 3,500+ real biopharma transactions.
Related Intelligence
ADC Benchmarks
Upfront, milestone, and royalty benchmarks for adc deals
Radiopharmaceuticals Benchmarks
Upfront, milestone, and royalty benchmarks for radiopharmaceuticals deals
Deal Pulse
Track the latest biopharma licensing and acquisition deals across all therapeutic areas
All Company Profiles
Browse 850+ biotech and pharma company profiles with deal history and pipeline data
2026 Deal Benchmarks Report
Industry-wide analysis of deal terms, trends, and market dynamics
About Regeneron Ophthalmology Licensing & Deal Activity
Regeneron Ophthalmology is a large biotech company based in US that has been actively engaged in licensing transactions across the biopharma landscape. With 4 deals over the past three years, Regeneron Ophthalmology ranks among the actively acquisitive companies tracked by Ambrosia Ventures.
Key therapeutic areas of focus for Regeneron Ophthalmology include Mega Deals (6 deals and trials), and Option Deals (1 deal and trial). In terms of modality, Regeneron Ophthalmology has shown particular interest in adc, radiopharmaceuticals, oligonucleotides.
Ambrosia Ventures tracks deal terms, pipeline data, patent expirations, and competitive positioning for Regeneron Ophthalmology and 850+ other biopharma companies. Use our deal calculator to benchmark your asset against Regeneron Ophthalmology's historical deal terms, or explore all company profiles to find the best partner match for your pipeline.